QC
LXRX icon

Quantessence Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Quantessence Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,581
Closed -$29K – 105
2026
Q1 		$29K Buy
+18,581
New +$27K 0.14% 61
2025
Q3 		– Sell
-84,098
Closed -$79.5K – 256
2025
Q2 		$79.5K Buy
+84,098
New +$54.5K 0.02% 177

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Quantessence Capital's LXRX Position: Q2 2026 in Review

Quantessence Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 18,581 shares — an estimated $29K sold.

Quantessence Capital first reported a position in LXRX in Q2 2025 and held it in 2 quarters. The position peaked at $79.5K in Q2 2025. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Quantessence Capital reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quantessence Capital sold 18,581 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $29K.
  • Quantessence Capital first reported a position in Lexicon Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Quantessence Capital's Lexicon Pharmaceuticals position peaked at $79.5K in Q2 2025.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Quantessence Capital's 13F filing for Q2 2026, filed 14 Aug 2026.